SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1/A
Document Type: EX-1.1
Date Filed: 2026-03-18
Accession Number: 0001493152-26-010642
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226010642/ex1-1.htm

Chunk 0 of 21
Word Count: 1440
Character Count: 8943

Document Content:

Exhibit

BIOVENTRIX,
INC.

UNDERWRITING
AGREEMENT

New
York, New York

The
Benchmark Company, LLC

Representative of the several underwriters named on Schedule 1 attached hereto

E. 58th Street, 17th Floor

New
York, NY 10155

Ladies
and Gentlemen:

The
undersigned, BioVentrix, Inc., a Delaware corporation (collectively with its subsidiaries and affiliates, the “Company”),
hereby confirms its agreement (this “Agreement”) with The Benchmark Company, LLC (hereinafter referred to as “you”
(including its correlatives) or the “Representative”), and with the other underwriters named on Schedule 1
hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called
the “Underwriters” or, individually, an “Underwriter” and if there are no Underwriters other than
the Representative, references to multiple Underwriters shall be disregarded and the term Representative shall have the same meaning
as Underwriter and all corresponding changes from plural to singular shall be deemed to have been made) as follows:

Purchase and Sale of Shares.

Firm Shares.

Nature and Purchase of Firm Shares.

On the basis of the representations and warranties herein contained, but subject to the terms and conditions herein set forth, the Company
agrees to issue and sell to the several Underwriters, an aggregate of [—] shares (“Firm Shares”) of the Company’s
common stock, $0.0001 par value per share (the “Common Stock”).

The Underwriters, severally and not jointly, agree to purchase from the Company the number of Firm Shares set forth opposite their respective
names on Schedule 1 attached hereto and made a part hereof at a purchase price of $[—] per share (93% of the per Firm Share offering
price). The Firm Shares are to be offered initially to the public at the offering price set forth on the cover page of the Prospectus
(as defined in Section 2.1.1 hereof).

Firm Shares Payment and Delivery.

Delivery and payment for the Firm Shares shall be made at 10:00 a.m., Eastern time, on [—] [—], 2026, or at such other time as shall
be agreed upon by the Representative and the Company, at the offices of Ellenoff Grossman & Schole LLP, 1345 Avenue of the Americas,
New York, NY 10105 (“Company Counsel”), or McGuireWoods LLP, 1251 Avenue of the Americas, 20th Floor, New
York, NY 10020 (“Representative Counsel”) or at such other place (or remotely by facsimile or other electronic transmission)
as shall be agreed upon by the Representative and the Company. The hour and date of delivery and payment for the Firm Shares is hereinafter
called the “Closing Date.”

Payment for the Firm Shares shall be made on the Closing Date by wire transfer in Federal (same day) funds, payable to the order of the
Company upon delivery of the certificates (in form and substance satisfactory to the Underwriters) representing the Firm Shares or through
the facilities of the Depository Trust Company (“DTC”) for the account of the Underwriters. The Firm Shares shall
be registered in such name or names and in such authorized denominations as the Representative may request in writing at least two (2)
full Business Days prior to the Closing Date. The Company shall not be obligated to sell or deliver the Firm Shares except upon tender
of payment by the Representative for all of the Firm Shares. The term “Business Day” means any day other than a Saturday,
a Sunday or a legal holiday or a day on which banking institutions are authorized or obligated by law to close in New York, New York.

Over-Allotment Option.

Solely for the purposes of covering any over-allotments in connection with the distribution and sale of the Firm Shares, the Representative
is hereby granted an option (the “Over-Allotment Option”) to purchase, in the aggregate, up to [—] shares of Common
Stock, representing 15% of the Firm Shares (the “Option Shares” and, collectively with the Firm Shares, the “Public
Shares” and the offering of the Public Shares, the Representative’s Warrants and the Representative Warrant Shares (each
as defined below) the “Offering”). If the Over-Allotment Option is exercised in whole or in part, the Option Shares
shall be purchased by the Underwriters in the amounts set forth opposite their respective names on Schedule 1 attached hereto
(or a pro rata portion thereof if less than the full Over-Allotment Option is exercised).

In connection with an exercise of the Over-Allotment Option, the aggregate purchase price to be paid for the Option Shares is equal to
the product of the number of Option Shares to be purchased multiplied by the same price per share paid by the Underwriters for the Firm
Shares as provided for in Section 1.1.1(ii).

The Over-Allotment Option granted pursuant to this Section 1.2 may be exercised by the Representative as to all (at any time) or any
part (from time to time) of the Option Shares within thirty (30) days after the Closing Date. An Underwriter will not be under any obligation
to purchase any Option Shares prior to the exercise of the Over-Allotment Option. The Over-Allotment Option granted hereby may be exercised
by the giving of written notice to the Company from the Representative, setting forth the number of Option Shares to be purchased and
the date and time for delivery of and payment for the Option Shares (each, an “Option Closing Date”), which will not
be later than two (2) full Business Days after the date of the notice or such other time as shall be agreed upon by the Company and the
Representative, at the offices of Company Counsel or at such other place (including remotely by facsimile or other electronic transmission)
as shall be agreed upon by the Company and the Representative. If such delivery and payment for the Option Shares does not occur on the
Closing Date, each Option Closing Date will be as set forth in the notice. Upon exercise of the Over-Allotment Option, the Company will
become obligated to convey to the Underwriters, and, subject to the terms and conditions set forth herein, the Underwriters will become
obligated to purchase, the number of Option Shares specified in such notice, provided that the Company’s obligation to sell and
deliver the Option Shares shall be conditioned upon the Representative’s tender of payment for the applicable Option Shares. The
Representative shall deliver the aggregate Option Closing Purchase Price to the Company on the Closing Date or any Option Closing Date.
The Representative may cancel the Over-Allotment Option at any time prior to the expiration of the Over-Allotment Option by written notice
to the Company.

Representative’s Warrants.

The Company hereby agrees to issue to the Representative (and/or its designees) on the Closing Date warrants for the purchase of the
number of shares of Common Stock equal to five percent (5%) of the total number of Firm Shares, and upon any Option Closing Date, five
percent (5%) of the total number of Option Shares sold on such Option Closing Date, in each case pursuant to a warrant substantially
in the form hereto as Exhibit C (the “Representative’s Warrants”). The Representative’s Warrants
shall be exercisable, in whole or in part, commencing on the date that is the first day of the seventh month after the Closing Date and
expiring on the five (5) year anniversary of the date of this Agreement, and shall be exercisable at an initial exercise price equal
to the public offering price per share, and may be exercised on a cashless basis. The shares of Common Stock issuable upon exercise of
the Representative’s Warrants are hereinafter referred to together as the “Representative Warrant Shares.” The
Representative understands and agrees that there are significant restrictions pursuant to FINRA Rule 5110 against transferring the Representative’s
Warrants and the Representative Warrant Shares during the 180 days after the commencement date of sales in the Offering and by its acceptance
thereof shall agree that it will not sell, transfer, assign, pledge or hypothecate the Representative’s Warrants, or any portion
thereof, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic
disposition of such securities for a period of 180 days after the commencement date of sales in the Offering, except as expressly permitted
by FINRA Rule 5110(e), and only if any such transferee agrees to the foregoing lock-up restrictions.

Delivery of the Representative’s Warrants shall be made on the Closing Date and any Option Closing Date, as applicable, and shall
be issued in the name or names and in such authorized denominations as the Representative may reasonably request.

Representations and Warranties of the Company. The Company hereby represents and warrants to the Underwriters as of the Applicable
Time (as defined below), the Closing Date and any Option Closing Date, as follows:

Filing of Registration Statement.